Loading…
Biotechnology company known for HIV treatments (Biktarvy) and prevention (Yeztugo/Descovy), also in oncology and liver disease.
Biotechnology company known for HIV treatments (Biktarvy) and prevention (Yeztugo/Descovy), also in oncology and liver disease.
Sells patented HIV medicines that patients stay on for years, so Biktarvy sales are steady and rely on keeping the prescription, alongside hepatitis C cures, the cancer drug Trodelvy and cell therapy through its Kite unit. Yeztugo, a twice-yearly prevention injection approved in 2025, is a new line.
Moat: wide (IP / patents, scale, regulatory licence). Category-leading HIV franchise built on patented combination therapies with very high patient switching costs.
Headquarters: Foster City, California, US · Founded: 1987 · Employees: 17,000
Size Gilead Sciences (GILD) is a United States Health Care company (Biotechnology) with a market value of $207B, the 54th largest of 3,117 United States companies the cockpit tracks. Shares closed at $166.89 on 6 Nov 2026.
Performance Over six months the shares gained 27.9%, against +39.3% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 7 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median -6.6%); the operating margin is 38.4% (peer median 27.3%).
Valuation It trades at 19.3× forward earnings against a peer median of 29.2× (2nd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 23.7 points above its cost of capital (6.5% WACC).
Credit Gilead Sciences has 22 bonds outstanding ($24.2B), rated A- by the agencies and trading like AA- at a weighted spread of 66 bp.
Short interest Short interest is 1.6% of the free float (15 Oct 2026).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $31.1B | $29.4B | $28.7B | $27.1B | $27.1B |
| Revenue growth | — | +3% | +6% | 0% | — |
| Gross profit | $24.9B | $23.2B | $22.5B | $21.0B | $21.4B |
| EBITDA | $14.7B | $14.6B | $13.4B | $12.4B | $12.9B |
| Net income | -$3.86B | $8.51B | $480M | $5.67B | $4.59B |
| Free cash flow | $13.8B | $9.46B | $10.3B | $7.42B | $8.34B |
| Capital expenditure | $699M | $563M | $523M | $585M | $728M |
| Total debt | $26.2B | $25.5B | $27.3B | $25.7B | $25.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gilead Sciences GILD | $207B | +28% | +7% | 38% | 19.3× | -2.9% |
| GSK GSK.L | $102B | 0% | +4% | 25% | 10.6× | -0.1% |
| Merck & MRK | $362B | +33% | +5% | 18% | 17.4× | 4.1% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 9.7× | -12.9% |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 18.4× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GILD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.4% | +13.1% | 3rd highest of 7 |
| 6-month return | +27.9% | +39.3% | 3rd lowest of 7 |
| Distance from 52-week high | -5.5% | -9.2% | 4th highest of 7 |
| Revenue growth (TTM) | +6.9% | -6.6% | 3rd highest of 7 |
| Operating margin | 38.4% | 27.3% | 2nd highest of 7 |
| Forward P/E | 19.3× | 29.2× | 2nd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | -2.9% | 9.6% | least demanding of 6 |
| Growth delivered (Del g) | +3.6% | +11.0% | lowest of 6 |
| Hurdle (Req g minus delivered) | -6.5 pp | -6.0 pp | 3rd least demanding of 6 |
| ROIC minus cost of capital | +23.7 pp | +8.8 pp | 2nd highest of 7 |
| EV / EBITDA | 15.3× | 19.3× | 2nd cheapest of 5 |
| Net debt / EBITDA | 1.2× | 1.8× | 2nd least indebted of 5 |
| Bond spread | 66 bp | 76 bp | tightest of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences GILD | United States | $207B | +28% | +7% | 38% | 19.3× | -2.9% | +3.6% |
| Amgen AMGN | United States | $249B | +40% | +9% | 36% | 18.9× | 1.8% | +7.8% |
| Moderna MRNA | United States | $101B | +43% | -28% | -149% | n/a | n/a | n/a |
| CSL CSL.AX | Australia | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% | +11.0% |
| argenx SE Sponsored ADR ARGX | United States | $57.5B | +19% | +71% | 29% | n/a | 10.9% | +151.4% |
| Lonza LONN.SW | Switzerland | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% | +7.7% |
| Samsung Biologics 207940.KS | South Korea | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% | +31.4% |
Gilead Sciences has 22 bonds outstanding with $24.2B face value. The agencies rate it A-; its bonds trade like AA-. Weighted yield 5.65%, a spread of 66 bp over government bonds.